CN115927212A - 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 - Google Patents

用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 Download PDF

Info

Publication number
CN115927212A
CN115927212A CN202210931466.8A CN202210931466A CN115927212A CN 115927212 A CN115927212 A CN 115927212A CN 202210931466 A CN202210931466 A CN 202210931466A CN 115927212 A CN115927212 A CN 115927212A
Authority
CN
China
Prior art keywords
bgag
vlps
vlp
virus
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210931466.8A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·普什科
伊丽娜·特蕾娅科娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigen Inc
Original Assignee
Medigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Inc filed Critical Medigen Inc
Publication of CN115927212A publication Critical patent/CN115927212A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
CN202210931466.8A 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 Pending CN115927212A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562188084P 2015-07-02 2015-07-02
US62/188,084 2015-07-02
CN201680050161.9A CN108348596B (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒
PCT/US2016/040838 WO2017004586A1 (en) 2015-07-02 2016-07-01 Recombinant virus like particles using bovine immunodeficiency virus gag protein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680050161.9A Division CN108348596B (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒

Publications (1)

Publication Number Publication Date
CN115927212A true CN115927212A (zh) 2023-04-07

Family

ID=57609369

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210931466.8A Pending CN115927212A (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒
CN201680050161.9A Active CN108348596B (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680050161.9A Active CN108348596B (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒

Country Status (13)

Country Link
US (2) US11576965B2 (https=)
EP (1) EP3316906A4 (https=)
JP (2) JP6978079B2 (https=)
KR (1) KR20180032586A (https=)
CN (2) CN115927212A (https=)
BR (1) BR112018000037A2 (https=)
CA (1) CA2991213A1 (https=)
EA (1) EA201890187A1 (https=)
MA (1) MA42312A (https=)
MX (1) MX390927B (https=)
PE (1) PE20180771A1 (https=)
RU (2) RU2757723C2 (https=)
WO (1) WO2017004586A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42312A (fr) * 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine
CN112279900A (zh) * 2020-12-30 2021-01-29 乾元浩生物股份有限公司 H9n2亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009008A1 (en) * 2003-07-11 2005-01-13 Robinson Robin A. Functional influenza virus-like particles (VLPs)
US20060216702A1 (en) * 2002-05-17 2006-09-28 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
CN101801412A (zh) * 2007-07-19 2010-08-11 诺瓦瓦克斯股份有限公司 水痘带状疱疹病毒-病毒样颗粒(vlp)和抗原
CN102676461A (zh) * 2011-03-17 2012-09-19 中国科学院上海巴斯德研究所 一种利用果蝇细胞生产病毒样颗粒的方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
WO2004042001A2 (en) 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
DE60335139D1 (de) * 2002-05-17 2011-01-05 Univ Emory Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
WO2008005777A2 (en) * 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
WO2008094200A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US20100247574A1 (en) 2007-02-21 2010-09-30 Kutub Mahmood CHIMERIC NEWCASTLE DISEASE VIRUS VLPs
SG10201509679XA (en) 2007-05-29 2015-12-30 Christopher B Reid Methods for production and uses of multipotent cell populations
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
AU2011258165B2 (en) * 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2015066715A1 (en) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
MA42312A (fr) * 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216702A1 (en) * 2002-05-17 2006-09-28 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US20050009008A1 (en) * 2003-07-11 2005-01-13 Robinson Robin A. Functional influenza virus-like particles (VLPs)
CN101801412A (zh) * 2007-07-19 2010-08-11 诺瓦瓦克斯股份有限公司 水痘带状疱疹病毒-病毒样颗粒(vlp)和抗原
CN102676461A (zh) * 2011-03-17 2012-09-19 中国科学院上海巴斯德研究所 一种利用果蝇细胞生产病毒样颗粒的方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAO-ZHONG WANG等: "Incorporation of High Levels of Chimeric Human Immunodeficiency Virus Envelope Glycoproteins into Virus-Like Particles", 《JOURNAL OF VIROLOGY》, vol. 18, no. 20, 31 October 2007 (2007-10-31) *
POLLY ROY等: "Virus-like particles as a vaccine delivery system: Myths and facts", 《HUMAN VACCINES》, vol. 4, no. 1, 2 January 2008 (2008-01-02) *

Also Published As

Publication number Publication date
RU2734118C2 (ru) 2020-10-13
WO2017004586A1 (en) 2017-01-05
US20180369364A1 (en) 2018-12-27
MA42312A (fr) 2018-05-09
US20230310579A1 (en) 2023-10-05
PE20180771A1 (es) 2018-05-07
MX2018000023A (es) 2018-08-15
MX390927B (es) 2025-03-21
JP6978079B2 (ja) 2021-12-08
EP3316906A1 (en) 2018-05-09
KR20180032586A (ko) 2018-03-30
US12303560B2 (en) 2025-05-20
CN108348596B (zh) 2022-08-23
RU2757723C2 (ru) 2021-10-21
JP2020198893A (ja) 2020-12-17
US11576965B2 (en) 2023-02-14
EP3316906A4 (en) 2019-01-02
RU2020125098A3 (https=) 2020-12-11
CA2991213A1 (en) 2017-01-05
JP2018525028A (ja) 2018-09-06
CN108348596A (zh) 2018-07-31
HK1259067A1 (zh) 2019-11-22
BR112018000037A2 (en) 2018-09-04
EA201890187A1 (ru) 2018-06-29
RU2020125098A (ru) 2020-09-04
RU2018103757A (ru) 2019-08-05
RU2018103757A3 (https=) 2019-12-09

Similar Documents

Publication Publication Date Title
Tretyakova et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses
US9849172B2 (en) Influenza virus vaccines and uses thereof
EP2010557B1 (en) High titer recombinant influenza viruses for vaccines
US12303560B2 (en) Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus
Smith et al. Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A (H5N1) virus infection in ferrets
EP4093415A1 (en) Recombinant influenza viruses with stabilized na
EP3840780A1 (en) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
KR20110113615A (ko) 인플루엔자 백신의 생산
US10369211B2 (en) Influenza H5 vaccines
Pushko et al. Mono-and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model
EP4351637A2 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
US20160361409A1 (en) H5 proteins of h5n1 influenza virus for use as a medicament
Chang et al. Production of immunogenic one-component avian H7-subtype influenza virus-like particles
HK40090606A (zh) 用牛免疫缺陷病毒gag蛋白的重组病毒样颗粒
HK1259067B (en) Recombinant virus like particles using bovine immunodeficiency virus gag protein
EA042635B1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
Walz Generation and evaluation of universal influenza vaccine candidates
Dlugolenski Passage of LPAIV H5 isolates in chickens results in genotypic changes in the glycoprotein genes and development of a species independent competitive ELISA system
Shehata Truncated Sequences of Influenza Subtype H5 Haemagglutinin for Vaccination and Diagnostic Purposes: Avian influenza, Yeast expression, Peptide vaccination, recombinant Elisa
KR20170029981A (ko) 고병원성 조류 인플루엔자(h5n1) 및 뉴캣슬병 바이러스 융합 바이러스 유사 입자 백신 및 이를 이용한 백신

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090606

Country of ref document: HK